Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
ConclusionsThis analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage mCRPC, particularly in patients under-represented in clinical studies.Trial RegistrationClinicalTrials.gov identifier NCT02236637; registered September 2014.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Docetaxel | Endocrinology | Heart | Prednisolone | Prednisone | Prostate Cancer | Study | Taxotere